

2019 -- S 0772 AS AMENDED

=====
LC002065
=====

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2019

—————
A N A C T

RELATING TO INSURANCE - ACCIDENT AND SICKNESS INSURANCE POLICIES -
STEP THERAPY PROTOCOLS

Introduced By: Senators Gallo, Conley, Goodwin, Lawson, and Pearson

Date Introduced: April 04, 2019

Referred To: Senate Health & Human Services

It is enacted by the General Assembly as follows:

1 SECTION 1. Chapter 27-18 of the General Laws entitled "Accident and Sickness
2 Insurance Policies" is hereby amended by adding thereto the following section:

3 **27-18-85. Step therapy protocol.**

4 (a) As used in this section the following words shall, unless the context clearly requires
5 otherwise, have the following meanings:

6 (1) "Clinical practice guidelines" means a systematically developed statement to assist
7 practitioner and patient decisions about appropriate health care for specific clinical circumstances.

8 (2) "Clinical review criteria" means the written screening procedures, decision abstracts,
9 clinical protocols and practice guidelines used by an insurer, health plan, or utilization review
10 organization to determine the medical necessity and appropriateness of health care services.

11 (3) "Step therapy exception" means a process that provides that a step therapy protocol
12 should be overridden in favor of immediate coverage of the health care provider's selected
13 prescription drug.

14 (4) "Step therapy protocol" means a protocol or program that establishes the specific
15 sequence in which prescription drugs for a specified medical condition that are medically
16 appropriate for a particular patient and are covered as a pharmacy or medical benefit, including
17 self-administered and physician-administered drugs, are covered by an insurer or health plan.

18 (5) "Utilization review organization" means an entity that conducts utilization review,

1 other than a health carrier performing utilization review for its own health benefit plans.

2 (b) Any policy, contract, agreement, plan or certificate of insurance issued, delivered or
3 renewed within the state that provides coverage for prescription drugs and uses step therapy
4 protocols shall have the following requirements and restrictions:

5 (1) Clinical review criteria used to establish step therapy protocols shall be based on
6 clinical practice guidelines:

7 (i) Independently developed by a multidisciplinary panel with expertise in the medical
8 condition, or conditions, for which coverage decisions said criteria will be applied; and

9 (ii) That recommend drugs be taken in the specific sequence required by the step therapy
10 protocol.

11 (c) When coverage of medications for the treatment of any medical condition are
12 restricted for use by an insurer, health plan, or utilization review organization via a step therapy
13 protocol, the patient and prescribing practitioner shall have access to a clear and convenient
14 process to request a step therapy exception. An insurer, health plan, or utilization review
15 organization shall use its existing medical exceptions process to satisfy this requirement. The
16 process shall be disclosed to the patient and health care providers, including documenting and
17 making easily accessible on the insurer's, health plan's or utilization review organization's
18 website.

19 (d) A step therapy override exception shall be expeditiously granted if:

20 (1) The required drug is contraindicated or will likely cause an adverse reaction, or
21 physical or mental harm to the patient;

22 (2) The required prescription drug is expected to be ineffective based on the known
23 clinical characteristics of the patient and the known characteristics of the prescription drug
24 regimen;

25 (3) The enrollee has tried the step therapy-required drug while under their current health
26 plan, or another drug in the same pharmacologic class or with the same mechanism of action and
27 such drugs were discontinued due to lack of efficacy or effectiveness, diminished effect, or an
28 adverse event;

29 (4) The patient is stable on a drug recommended by their health care provider for the
30 medical condition under consideration while on a current or previous health insurance or health
31 benefit plan and no generic substitution is available. This subsection shall not be construed to
32 allow the use of a pharmaceutical sample to meet the requirements for a step therapy override
33 exception.

34 (e) Upon the granting of a step therapy override exception request, the insurer, health

1 plan, utilization review organization, or other entity shall authorize coverage for the drug
2 prescribed by the enrollee's treating health care provider, provided such drug is a covered drug
3 under such terms of policy or contract.

4 (f) The insurer, health plan, or utilization review organization shall grant or deny a step
5 therapy exception request or an appeal within seventy-two (72) hours of receipt. In cases where
6 exigent circumstances exist an insurer, health plan, or utilization review organization shall grant
7 or deny a step therapy exception request or an appeal within twenty-four (24) hours of receipt.
8 Should a grant or denial by an insurer, health plan, or utilization review organization not be
9 received within the time allotted, the exception or appeal shall be deemed granted.

10 (g) Any step therapy exception as defined by this subsection shall be eligible for appeal
11 by an insured.

12 (h) This section shall not be construed to prevent:

13 (1) An insurer, health plan, or utilization review organization from requiring an enrollee
14 to try an AB-rated generic equivalent prior to providing reimbursement for the equivalent
15 branded drug;

16 (2) A health care provider from prescribing a drug they determine is medically
17 appropriate.

18 (i) The health insurance commissioner may promulgate such rules and regulations,
19 including rules and regulations under chapter 18.9 of title 27, the benefit determination and
20 utilization review act, as are necessary and proper to effectuate the purpose and for the efficient
21 administration and enforcement of this section entitled "step therapy protocol", as well as to
22 effectuate the coordination of the efficient administration and enforcement of this section with the
23 act.

24 SECTION 2. Chapter 27-19 of the General Laws entitled "Nonprofit Hospital Service
25 Corporations" is hereby amended by adding thereto the following section:

26 **27-19-77. Step therapy protocol.**

27 (a) As used in this section the following words shall, unless the context clearly requires
28 otherwise, have the following meanings:

29 (1) "Clinical practice guidelines" means a systematically developed statement to assist
30 practitioner and patient decisions about appropriate health care for specific clinical circumstances.

31 (2) "Clinical review criteria" means the written screening procedures, decision abstracts,
32 clinical protocols and practice guidelines used by an insurer, health plan, or utilization review
33 organization to determine the medical necessity and appropriateness of health care services.

34 (3) "Step therapy exception" means a process that provides that a step therapy protocol

1 should be overridden in favor of immediate coverage of the health care provider's selected
2 prescription drug.

3 (4) "Step therapy protocol" means a protocol or program that establishes the specific
4 sequence in which prescription drugs for a specified medical condition that are medically
5 appropriate for a particular patient and are covered as a pharmacy or medical benefit, including
6 self-administered and physician-administered drugs, are covered by an insurer or health plan.

7 (5) "Utilization review organization" means an entity that conducts utilization review,
8 other than a health carrier performing utilization review for its own health benefit plans.

9 (b) Any policy, contract, agreement, plan or certificate of insurance issued, delivered or
10 renewed within the state that provides coverage for prescription drugs and uses step therapy
11 protocols shall have the following requirements and restrictions:

12 (1) Clinical review criteria used to establish step therapy protocols shall be based on
13 clinical practice guidelines:

14 (i) Independently developed by a multidisciplinary panel with expertise in the medical
15 condition, or conditions, for which coverage decisions said criteria will be applied; and

16 (ii) That recommend drugs be taken in the specific sequence required by the step therapy
17 protocol.

18 (c) When coverage of medications for the treatment of any medical condition are
19 restricted for use by an insurer, health plan, or utilization review organization via a step therapy
20 protocol, the patient and prescribing practitioner shall have access to a clear and convenient
21 process to request a step therapy exception. An insurer, health plan, or utilization review
22 organization shall use its existing medical exceptions process to satisfy this requirement. The
23 process shall be disclosed to the patient and health care providers, including documenting and
24 making easily accessible on the insurer's, health plan's or utilization review organization's
25 website.

26 (d) A step therapy override exception shall be expeditiously granted if:

27 (1) The required drug is contraindicated or will likely cause an adverse reaction, or
28 physical or mental harm to the patient;

29 (2) The required prescription drug is expected to be ineffective based on the known
30 clinical characteristics of the patient and the known characteristics of the prescription drug
31 regimen;

32 (3) The enrollee has tried the step therapy-required drug while under their current health
33 plan, or another drug in the same pharmacologic class or with the same mechanism of action and
34 such drugs were discontinued due to lack of efficacy or effectiveness, diminished effect, or an

1 adverse event:

2 (4) The patient is stable on a drug recommended by their health care provider for the
3 medical condition under consideration while on a current or previous health insurance or health
4 benefit plan and no generic substitution is available. This subsection shall not be construed to
5 allow the use of a pharmaceutical sample to meet the requirements for a step therapy override
6 exception.

7 (e) Upon the granting of a step therapy override exception request, the insurer, health
8 plan, utilization review organization, or other entity shall authorize coverage for the drug
9 prescribed by the enrollee's treating health care provider, provided such drug is a covered drug
10 under such terms of policy or contract.

11 (f) The insurer, health plan, or utilization review organization shall grant or deny a step
12 therapy exception request or an appeal within seventy-two (72) hours of receipt. In cases where
13 exigent circumstances exist an insurer, health plan, or utilization review organization shall grant
14 or deny a step therapy exception request or an appeal within twenty-four (24) hours of receipt.
15 Should a grant or denial by an insurer, health plan, or utilization review organization not be
16 received within the time allotted, the exception or appeal shall be deemed granted.

17 (g) Any step therapy exception as defined by this subsection shall be eligible for appeal
18 by an insured.

19 (h) This section shall not be construed to prevent:

20 (1) An insurer, health plan, or utilization review organization from requiring an enrollee
21 to try an AB-rated generic equivalent prior to providing reimbursement for the equivalent
22 branded drug;

23 (2) A health care provider from prescribing a drug they determine is medically
24 appropriate.

25 (i) The health insurance commissioner may promulgate such rules and regulations,
26 including rules and regulations under chapter 18.9 of title 27, the benefit determination and
27 utilization review act, as are necessary and proper to effectuate the purpose and for the efficient
28 administration and enforcement of this section entitled "step therapy protocol", as well as to
29 effectuate the coordination of the efficient administration and enforcement of this section with the
30 act.

31 SECTION 3. Chapter 27-20 of the General Laws entitled "Nonprofit Medical Service
32 Corporations" is hereby amended by adding thereto the following section:

33 **27-20-73. Step therapy protocol.**

34 (a) As used in this section the following words shall, unless the context clearly requires

1 otherwise, have the following meanings:

2 (1) "Clinical practice guidelines" means a systematically developed statement to assist
3 practitioner and patient decisions about appropriate health care for specific clinical circumstances.

4 (2) "Clinical review criteria" means the written screening procedures, decision abstracts,
5 clinical protocols and practice guidelines used by an insurer, health plan, or utilization review
6 organization to determine the medical necessity and appropriateness of health care services.

7 (3) "Step therapy exception" means a process that provides that a step therapy protocol
8 should be overridden in favor of immediate coverage of the health care provider's selected
9 prescription drug.

10 (4) "Step therapy protocol" means a protocol or program that establishes the specific
11 sequence in which prescription drugs for a specified medical condition that are medically
12 appropriate for a particular patient and are covered as a pharmacy or medical benefit, including
13 self-administered and physician-administered drugs, are covered by an insurer or health plan.

14 (5) "Utilization review organization" means an entity that conducts utilization review,
15 other than a health carrier performing utilization review for its own health benefit plans.

16 (b) Any policy, contract, agreement, plan or certificate of insurance issued, delivered or
17 renewed within the state that provides coverage for prescription drugs and uses step therapy
18 protocols shall have the following requirements and restrictions:

19 (1) Clinical review criteria used to establish step therapy protocols shall be based on
20 clinical practice guidelines:

21 (i) Independently developed by a multidisciplinary panel with expertise in the medical
22 condition, or conditions, for which coverage decisions said criteria will be applied; and

23 (ii) That recommend drugs be taken in the specific sequence required by the step therapy
24 protocol.

25 (c) When coverage of medications for the treatment of any medical condition are
26 restricted for use by an insurer, health plan, or utilization review organization via a step therapy
27 protocol, the patient and prescribing practitioner shall have access to a clear and convenient
28 process to request a step therapy exception. An insurer, health plan, or utilization review
29 organization shall use its existing medical exceptions process to satisfy this requirement. The
30 process shall be disclosed to the patient and health care providers, including documenting and
31 making easily accessible on the insurer's, health plan's or utilization review organization's
32 website.

33 (d) A step therapy override exception shall be expeditiously granted if:

34 (1) The required drug is contraindicated or will likely cause an adverse reaction, or

1 physical or mental harm to the patient;

2 (2) The required prescription drug is expected to be ineffective based on the known
3 clinical characteristics of the patient and the known characteristics of the prescription drug
4 regimen;

5 (3) The enrollee has tried the step therapy-required drug while under their current health
6 plan, or another drug in the same pharmacologic class or with the same mechanism of action and
7 such drugs were discontinued due to lack of efficacy or effectiveness, diminished effect, or an
8 adverse event;

9 (4) The patient is stable on a drug recommended by their health care provider for the
10 medical condition under consideration while on a current or previous health insurance or health
11 benefit plan and no generic substitution is available. This subsection shall not be construed to
12 allow the use of a pharmaceutical sample to meet the requirements for a step therapy override
13 exception.

14 (e) Upon the granting of a step therapy override exception request, the insurer, health
15 plan, utilization review organization, or other entity shall authorize coverage for the drug
16 prescribed by the enrollee's treating health care provider, provided such drug is a covered drug
17 under such terms of policy or contract.

18 (f) The insurer, health plan, or utilization review organization shall grant or deny a step
19 therapy exception request or an appeal within seventy-two (72) hours of receipt. In cases where
20 exigent circumstances exist an insurer, health plan, or utilization review organization shall grant
21 or deny a step therapy exception request or an appeal within twenty-four (24) hours of receipt.
22 Should a grant or denial by an insurer, health plan, or utilization review organization not be
23 received within the time allotted, the exception or appeal shall be deemed granted.

24 (g) Any step therapy exception as defined by this subsection shall be eligible for appeal
25 by an insured.

26 (h) This section shall not be construed to prevent:

27 (1) An insurer, health plan, or utilization review organization from requiring an enrollee
28 to try an AB-rated generic equivalent prior to providing reimbursement for the equivalent
29 branded drug;

30 (2) A health care provider from prescribing a drug they determine is medically
31 appropriate.

32 (i) The health insurance commissioner may promulgate such rules and regulations,
33 including rules and regulations under chapter 18.9 of title 27, the benefit determination and
34 utilization review act, as are necessary and proper to effectuate the purpose and for the efficient

1 administration and enforcement of this section entitled "step therapy protocol", as well as to
2 effectuate the coordination of the efficient administration and enforcement of this section with the
3 act.

4 SECTION 4. Chapter 27-41 of the General Laws entitled "Health Maintenance
5 Organizations" is hereby amended by adding thereto the following section:

6 **27-41-90. Step therapy protocol.**

7 (a) As used in this section the following words shall, unless the context clearly requires
8 otherwise, have the following meanings:

9 (1) "Clinical practice guidelines" means a systematically developed statement to assist
10 practitioner and patient decisions about appropriate health care for specific clinical circumstances.

11 (2) "Clinical review criteria" means the written screening procedures, decision abstracts,
12 clinical protocols and practice guidelines used by an insurer, health plan, or utilization review
13 organization to determine the medical necessity and appropriateness of health care services.

14 (3) "Step therapy exception" means a process that provides that a step therapy protocol
15 should be overridden in favor of immediate coverage of the health care provider's selected
16 prescription drug.

17 (4) "Step therapy protocol" means a protocol or program that establishes the specific
18 sequence in which prescription drugs for a specified medical condition that are medically
19 appropriate for a particular patient and are covered as a pharmacy or medical benefit, including
20 self-administered and physician-administered drugs, are covered by an insurer or health plan.

21 (5) "Utilization review organization" means an entity that conducts utilization review,
22 other than a health carrier performing utilization review for its own health benefit plans.

23 (b) Any policy, contract, agreement, plan or certificate of insurance issued, delivered or
24 renewed within the state that provides coverage for prescription drugs and uses step therapy
25 protocols shall have the following requirements and restrictions:

26 (1) Clinical review criteria used to establish step therapy protocols shall be based on
27 clinical practice guidelines:

28 (i) Independently developed by a multidisciplinary panel with expertise in the medical
29 condition, or conditions, for which coverage decisions said criteria will be applied; and

30 (ii) That recommend drugs be taken in the specific sequence required by the step therapy
31 protocol.

32 (c) When coverage of medications for the treatment of any medical condition are
33 restricted for use by an insurer, health plan, or utilization review organization via a step therapy
34 protocol, the patient and prescribing practitioner shall have access to a clear and convenient

1 process to request a step therapy exception. An insurer, health plan, or utilization review
2 organization shall use its existing medical exceptions process to satisfy this requirement. The
3 process shall be disclosed to the patient and health care providers, including documenting and
4 making easily accessible on the insurer's, health plan's or utilization review organization's
5 website.

6 (d) A step therapy override exception shall be expeditiously granted if:

7 (1) The required drug is contraindicated or will likely cause an adverse reaction, or
8 physical or mental harm to the patient;

9 (2) The required prescription drug is expected to be ineffective based on the known
10 clinical characteristics of the patient and the known characteristics of the prescription drug
11 regimen;

12 (3) The enrollee has tried the step therapy-required drug while under their current health
13 plan, or another drug in the same pharmacologic class or with the same mechanism of action and
14 such drugs were discontinued due to lack of efficacy or effectiveness, diminished effect, or an
15 adverse event;

16 (4) The patient is stable on a drug recommended by their health care provider for the
17 medical condition under consideration while on a current or previous health insurance or health
18 benefit plan and no generic substitution is available. This subsection shall not be construed to
19 allow the use of a pharmaceutical sample to meet the requirements for a step therapy override
20 exception.

21 (e) Upon the granting of a step therapy override exception request, the insurer, health
22 plan, utilization review organization, or other entity shall authorize coverage for the drug
23 prescribed by the enrollee's treating health care provider, provided such drug is a covered drug
24 under such terms of policy or contract.

25 (f) The insurer, health plan, or utilization review organization shall grant or deny a step
26 therapy exception request or an appeal within seventy-two (72) hours of receipt. In cases where
27 exigent circumstances exist an insurer, health plan, or utilization review organization shall grant
28 or deny a step therapy exception request or an appeal within twenty-four (24) hours of receipt.
29 Should a grant or denial by an insurer, health plan, or utilization review organization not be
30 received within the time allotted, the exception or appeal shall be deemed granted.

31 (g) Any step therapy exception as defined by this subsection shall be eligible for appeal
32 by an insured.

33 (h) This section shall not be construed to prevent:

34 (1) An insurer, health plan, or utilization review organization from requiring an enrollee

1 to try an AB-rated generic equivalent prior to providing reimbursement for the equivalent
2 branded drug;

3 (2) A health care provider from prescribing a drug they determine is medically
4 appropriate.

5 (i) The health insurance commissioner may promulgate such rules and regulations,
6 including rules and regulations under chapter 18.9 of title 27, the benefit determination and
7 utilization review act, as are necessary and proper to effectuate the purpose and for the efficient
8 administration and enforcement of this section entitled "step therapy protocol", as well as to
9 effectuate the coordination of the efficient administration and enforcement of this section with the
10 act.

11 SECTION 5. This act shall take effect upon passage and shall apply only to health
12 insurance and health benefit plans delivered, issued for delivery, or renewed on or after January 1,
13 2020.

=====
LC002065
=====

EXPLANATION
BY THE LEGISLATIVE COUNCIL
OF

A N A C T

RELATING TO INSURANCE - ACCIDENT AND SICKNESS INSURANCE POLICIES -
STEP THERAPY PROTOCOLS

1 This act would require health insurers, nonprofit hospital service corporations, nonprofit
2 medical service corporations and health maintenance organizations that issue policies that provide
3 coverage for prescription drugs and use step therapy protocols, to base step therapy protocols on
4 appropriate clinical practice guidelines or published peer review data developed by independent
5 experts with knowledge of the condition or conditions under consideration; that patients be
6 exempt from step therapy protocols when inappropriate; and that patients have access to a fair,
7 transparent and independent process for requesting an exception to a step therapy protocol when
8 the patient's physician deems appropriate.

9 This act would take effect upon passage and shall apply only to health insurance and
10 health benefit plans delivered, issued for delivery, or renewed on or after January 1, 2020.

=====
LC002065
=====